AI is moving into the NHS. Is your HealthTech brand ready for the scrutiny that comes with it?
AI in the NHS is no longer an experimental sideline. The government's 10 Year Health Plan for England, published in July 2025, places a shift from analogue to digital at the centre of NHS reform, with AI and digital technology treated as core enablers rather than optional extras.
Alongside that, the MHRA established a National Commission into the Regulation of AI in Healthcare in September 2025, which published its recommendations for a future regulatory framework on 10 September 2026. The direction of travel is clear: more AI, and more structured scrutiny of it.
For companies marketing AI-enabled healthcare technology, that combination changes what good marketing looks like.
Scrutiny arrives before procurement does
When a category attracts national policy attention, buyers become better informed and more cautious at the same time. The people assessing your product will increasingly have read the guidance, seen several competing pitches, and developed a sharp instinct for claims that are doing more work than the evidence behind them.
That scrutiny starts long before a formal process. It starts on your website, in your LinkedIn posts and in the deck someone forwards to a colleague.
Say precisely what the AI does
The most common problem we see in AI healthcare marketing is imprecision: AI-powered as a badge rather than a description. It creates two risks. Commercially, it makes you interchangeable with every other supplier using the same phrase. Practically, it invites the buyer to assume a capability you may not be claiming.
Describe the function, the input, the output, and where a human sits in the process. Specificity is not a limitation on your marketing, it is the thing that distinguishes you from the noise.
Treat responsible claims as a commercial asset
In a market under scrutiny, restraint reads as confidence. Claims that are careful, dated and supportable travel better through a buying committee than claims that have to be walked back in the second meeting.
Being explicit about what your product does not do is unusual enough in this sector that it becomes a differentiator.
Make evidence legible
Evaluation work, deployment experience and published findings are often buried in documents nobody outside the project reads. If evidence exists, it should have a clear, public, plain-language presentation on your website, not only a PDF attached to a tender response.
Where this sits
This is a commentary on marketing and positioning. Regulatory classification, clinical safety and assurance obligations are matters for the MHRA guidance itself and for specialists in those fields. Our role is making sure the market understands what you have built.
This article refers to a position current at the date above and is reviewed when the underlying guidance or policy changes. Clarity Media Co. comments on the marketing and commercial implications of developments in Digital Health and HealthTech. We do not provide clinical, regulatory, DTAC or legal advice.
Sources
- Department of Health and Social Care — Fit for the Future: 10 Year Health Plan for England (July 2025)
- MHRA — National Commission into the Regulation of AI in Healthcare: recommendations for a future regulatory framework (10 September 2026)
- MHRA — AI Airlock: the regulatory sandbox for AI as a Medical Device